Table 3.
Surrogate TCGA molecular groups including β-catenin altered subgroup. Values are counts (percentages) or mean ± standard deviation [interquartile range].
| Clinicopathologic Characteristics |
POLE | MMRd | p53abn | β-CATabn | NSMP | p-Value |
|---|---|---|---|---|---|---|
| (n = 9; 7.2%) | (n = 41; 32.8%) | (n = 26; 20.8%) | (n = 16; 12.8%) | (n = 33; 26.4%) | ||
| Age, years | 61.2 ± 13.9 | 64.2 ± 10.0 | 65.0 ± 10.0 | 54.3 ± 12.9 | 63.6 ± 8.5 | 0.067 |
| [52–71] | [57–73] | [59–74] | [44–63] | [58–70] | ||
| Body mass index, kg/m2 | 25.3 ± 4.6 | 26.8 ± 6.1 | 25.4 ± 4.1 | 29.0 ± 6.7 | 29.7 ± 8.3 | 0.187 |
| [21.3–28.1] | [22.7–28.2] | [22.8–27.2] | [22.5–33.5] | [24.2–36.1] | ||
| Tumor type | <0.001 | |||||
| Endometrioid | 8 (88.9) | 30 (73.2) | 7 (26.9) | 14 (87.5) | 31 (93.9) | |
| Dedifferentiated/ Undifferentiated |
1 (11.1) | 11 (26.8) | 1 (3.8) | 2 (12.5) | 2 (6.1) | |
| Serous | 0 (0.0) | 0 (0.0) | 15 (57.7) | 0 (0) | 0 (0) | |
| Clear cell | 0 (0.0) | 0 (0.0) | 3 (11.5) | 0 (0) | 0 (0) | |
| Heterogeneity | 4 (44.4) | 21 (51.2) | 10 (38.5) | 5 (31.3) | 9 (27.3) | 0.290 |
| Grade | <0.001 | |||||
| 1 | 2 (22.2) | 11 (26.8) | 1 (3.8) | 8 (50.0) | 14 (42.4) | |
| 2 | 3 (33.3) | 14 (34.1) | 0 (0.0) | 5 (31.3) | 13 (39.4) | |
| 3 | 4 (44.4) | 16 (39.0) | 25 (96.2) | 3 (18.8) | 6 (18.2) | |
| Depth of invasion ≥50% | 1 (11.1) | 15 (36.6) | 9 (34.6) | 3 (18.8) | 7 (21.2) | 0.361 |
| LVSI | 2 (22.2) | 14 (34.1) | 11 (42.3) | 3 (18.8) | 7 (21.2) | 0.350 |
| Lymph node status | 0.193 | |||||
| Negative | 8 (88.9) | 31 (75.6) | 15 (57.7) | 15 (93.8) | 26 (78.8) | |
| Positive | 1 (11.1) | 8 (19.5) | 10 (38.5) | 1 (6.3) | 4 (12.1) | |
| Unknown/Not tested | 0 (0.0) | 2 (4.9) | 1 (3.8) | 0 (0.0) | 3 (9.1) | |
| FIGO stage | 0.048 | |||||
| IA | 5 (55.6) | 19 (46.3) | 12 (46.2) | 11 (68.8) | 24 (72.7) | |
| IB/II | 2 (22.2) | 12 (29.3) | 1 (3.8) | 3 (18.8) | 4 (12.1) | |
| III | 2 (22.2) | 9 (22.0) | 12 (46.2) | 2 (12.5) | 5 (15.2) | |
| IV | 0 (0.0) | 1 (2.4) | 1 (3.8) | 0 (0.0) | 0 (0.0) | |
| Extensive necrosis | 6 (66.7) | 23 (56.1) | 11 (42.3) | 4 (25.0) | 15 (45.5) | 0.195 |
| MELF | 5 (55.6) | 24 (58.5) | 3 (11.5) | 4 (25.0) | 10 (30.3) | 0.001 |
| Tumor budding | 7 (77.8) | 23 (56.1) | 8 (30.8) | 4 (25.0) | 10 (30.3) | 0.011 |
| High sTILs | 9 (100.0) | 35 (85.4) | 19 (73.1) | 7 (43.8) | 19 (57.6) | 0.002 |
| High iTILs | 9 (100.0) | 37 (90.2) | 17 (65.4) | 4 (25.0) | 19 (57.6) | <0.001 |
| Mitoses/10 HPF | 78.1 ± 34.5 | 55.3 ± 23.7 | 86.3 ± 43.7 | 30.5 ± 30.1 | 34.6 ± 26.8 | <0.001 |
| [50–103] | [40–70] | [45–130] | [9–44] | [20–40] | ||
| Ki67 proliferative index | 58.5 ± 14.9 | 57.9 ± 14.9 | 56.0 ± 16.7 | 35.9 ± 21.6 | 36.9 ± 16.6 | <0.001 |
| [55.1–68.2] | [47.1–69.6] | [49.3–69.7] | [17.1–58.4] | [25.3–42.7] |